← All trials
NCT05223686
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2022
- Primary completion
- Jun 10, 2023
- Completion date
- Mar 10, 2025
- First posted
- Feb 4, 2022
- Last posted
- Feb 4, 2022
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hrain Biotechnology Co., Ltd.Lead sponsor
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.